EMERGING REGULATORY FRAMEWORK FOR PHARMACEUTICALS AND COSMETICS IN INDIA: CURRENT PERSPECTIVES AND FUTURE CHALLENGES

EMERGING REGULATORY FRAMEWORK FOR PHARMACEUTICALS AND COSMETICS IN INDIA: CURRENT PERSPECTIVES AND FUTURE CHALLENGES

V. S. Kanaka *, K. Srathika, S. Deepu, R. Ranitha, Neenu Anna Thomas, R. Apsara, M. Nehanaz, T. Sandwana, M. Sumaya Fathima and M. Sunaina

Department of Pharmaceutics, Ahalia School of Pharmacy, Kozhippara, Palakkad, Kerala, India.

ABSTRACT: The pharmaceutical and cosmetic sectors contribute significantly to healthcare improvement, disease prevention, and personal care by providing safe and effective products to consumers. Continuous industrial expansion, globalization, technological innovation, and the increasing use of online healthcare platforms have emphasized the importance of strong regulatory systems for maintaining product safety, efficacy, and quality standards. In India, regulation of pharmaceutical and cosmetic products is primarily governed by the Drugs and Cosmetics Act, 1940, Drugs and Cosmetics Rules, 1945, and Cosmetic Rules 2020 under the supervision of the Central Drugs Standard Control Organization (CDSCO). This review provides a comprehensive overview of the Indian regulatory framework related to pharmaceuticals and cosmetics with particular focus on CDSCO, regulatory policies, Certificate of Pharmaceutical Product (COPP), Certificate of Analysis (COA), import-export licensing, Cosmetic Rules 2020, Drugs and Cosmetics Act and Rules, Good Manufacturing Practices (GMP), online sale regulations, and regulatory considerations associated with pediatric and geriatric products. The review additionally discusses the significance of pharmacovigilance programs, quality assurance systems, digital regulatory advancements, and harmonization with international guidelines established by WHO and ICH. Major challenges including counterfeit medicines, regulation of e-pharmacies, documentation requirements, and global regulatory harmonization are also critically evaluated. The review concludes that continuous strengthening of regulatory infrastructure, adoption of advanced digital technologies, modernization of compliance systems, and implementation of coordinated regulatory reforms are necessary to improve consumer protection, healthcare quality, and international competitiveness of the Indian pharmaceutical and cosmetic industries.

Keywords: CDSCO, Pharmaceutical Regulation, Cosmetic Rules 2020, GMP, COPP, COA, Regulatory Affairs, Drugs and Cosmetics Act, E-Pharmacy, Pharmacovigilance, Import-Export Licensing, Cosmetic Regulation

INTRODUCTION:

Overview of Pharmaceutical and Cosmetic Industries: The pharmaceutical and cosmetic industries are important sectors contributing significantly toward healthcare advancement, disease management, personal care, and economic development worldwide ¹.

India has emerged as one of the leading manufacturers of pharmaceutical formulations, generic medicines, and vaccines, supplying products to both domestic and international markets ².

Simultaneously, the cosmetic industry has experienced considerable growth because of increased consumer awareness, urbanization, changing lifestyle patterns, and rising demand for personal care products ³. The rapid expansion of these industries has increased the necessity for efficient regulatory systems capable of ensuring the safety, efficacy, and quality of pharmaceutical and cosmetic products before they reach consumers ⁴.

Need for Regulatory Control: Regulatory control is considered an essential component within pharmaceutical and cosmetic industries because it ensures compliance with legal and scientific standards associated with product development, manufacturing, import, export, marketing, and distribution activities ⁵. In India, pharmaceutical and cosmetic products are mainly regulated under the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945, which provide the legal framework for controlling the manufacture, sale, and distribution of these products ⁶. Proper regulatory systems help in minimizing risks associated with counterfeit medicines, adulterated products, substandard formulations, and misleading cosmetic claims while improving consumer safety and healthcare quality ⁷.

Importance of Regulatory Affairs in Public Health: Regulatory affairs play an important role in protecting public health by ensuring that pharmaceutical and cosmetic products comply with prescribed standards of safety, efficacy, and quality before entering the market ⁸. Regulatory authorities monitor product development, clinical evaluation, manufacturing practices, labeling requirements, quality assurance systems, and post-marketing surveillance activities associated with healthcare products ⁹. Effective regulatory systems contribute toward reduction of adverse drug reactions, prevention of unsafe products, and maintenance of consistent quality standards within healthcare systems ¹⁰. Regulatory affairs also facilitate international trade and harmonization of pharmaceutical standards through implementation of globally accepted regulatory guidelines ¹¹.

Scope and Objectives of the Review: The scope of this review is focused on the regulatory framework governing pharmaceuticals and cosmetics in India, with particular emphasis on the role of the Central Drugs Standard Control Organization (CDSCO) in ensuring product safety, efficacy, quality, and regulatory compliance. Rather than discussing individual regulatory topics as separate entities, the review presents an integrated perspective of the regulatory lifecycle encompassing product development, approval, manufacturing, quality assurance, import-export control, post marketing surveillance, and international harmonization.

Key regulatory components including Good Manufacturing Practices (GMP), Certificate of Pharmaceutical Product (COPP), Certificate of Analysis (COA), import-export licensing, online sale regulations, and regulatory considerations for pediatric and geriatric products are discussed in relation to their contribution to regulatory compliance and public health protection. The review further examines the impact of Cosmetic Rules 2020 and ongoing regulatory reforms aimed at improving transparency, digitalization, and harmonization with international standards. Through this integrated approach, the review highlights current regulatory advancements, existing challenges, and future opportunities for strengthening pharmaceutical and cosmetic regulation in India ⁵⁰.

MATERIALS AND METHODS: A detailed and structured literature review was carried out to collect and analyze relevant information on the pharmaceutical and cosmetic regulatory framework in India. The review included published research articles, review papers, regulatory guidelines, and official government documents.

Related literature was identified using scientific databases such as PubMed, Google Scholar, Scopus, and ScienceDirect. In addition, authoritative regulatory sources including the Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare (MoHFW), World Health Organization (WHO), International Council for Harmonisation (ICH), and Directorate General of Foreign Trade (DGFT) were consulted.

A combination of keywords was used for the search strategy, including pharmaceutical regulation in India, Drugs and Cosmetics Act, CDSCO, Cosmetic Rules 2020 GMP, COPP, COA, and e-pharmacy regulations.

The review included literature published between 2010 and 2026 to ensure coverage of both foundational regulatory frameworks and recent developments. Only English-language articles and officially published regulatory documents were considered. Studies and documents were included if they discussed pharmaceutical or cosmetic regulatory systems, legal frameworks, compliance requirements, or implementation aspects in India. Articles not related to regulatory affairs or lacking scientific or official validation were excluded. The selection process involved screening of titles and abstracts followed by full text evaluation. Only relevant and high-quality literature that directly addressed the objectives of the review was included in the final analysis.

Central Drugs Standard Control Organization (CDSCO):

Introduction to CDSCO: The Central Drugs Standard Control Organization (CDSCO), functioning under the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare, is India's national regulatory authority for drugs, cosmetics, medical devices, and clinical trials. Headed by the Drug Controller General of India (DCGI), CDSCO is responsible for the approval of new drugs, vaccines, biological products, clinical trials, and imported drugs and cosmetics, while State Licensing Authorities (SLAs) regulate manufacturing, sale, and distribution within their respective states. To improve regulatory efficiency and transparency, CDSCO has implemented the SUGAM online portal for electronic submission and processing of applications related to approvals, licenses, and registrations. The organization adopts risk-based inspection mechanisms, pharmacovigilance programs, and post-marketing surveillance activities to ensure product safety, efficacy, and quality. Through close coordination with SLAs, including joint inspections and information sharing, CDSCO ensures uniform implementation of the Drugs and Cosmetics Act, 1940, New Drugs and Clinical Trials Rules, 2019, and Cosmetic Rules, 2020, while promoting harmonization with international standards established by the World Health Organization (WHO) and the International Council for Harmonisation (ICH) ⁴⁹.

Organizational Structure of CDSCO: CDSCO is headed by the Drug Controller General of India (DCGI), who acts as the chief regulatory authority responsible for approval and supervision of pharmaceutical and cosmetic products in India ¹⁵. The organization operates through headquarters located in New Delhi along with zonal offices, sub-zonal offices, port offices, and central drug testing laboratories situated across different regions of the country ¹³. The zonal and sub-zonal offices mainly conduct inspections and coordinate regulatory activities associated with pharmaceutical and cosmetic products, while port offices monitor import and export of healthcare products entering the country through airports, seaports, and land ports ¹⁶. Central drug testing laboratories under CDSCO are responsible for analytical testing and quality evaluation of pharmaceutical and cosmetic products to ensure compliance with established standards ⁸. CDSCO also collaborates with State Drug Control Authorities for effective implementation and enforcement of regulatory provisions throughout India ⁴.

Functions and Responsibilities of CDSCO: CDSCO performs several important functions related to regulation of pharmaceutical and cosmetic products in India. One of its primary responsibilities is approval of new drugs before their introduction into the market ⁵. The organization evaluates preclinical and clinical data to assess the safety, efficacy, and therapeutic effectiveness of pharmaceutical products ¹⁰. CDSCO is also responsible for regulation of clinical trials conducted in India by ensuring compliance with ethical guidelines, patient safety requirements, and Good Clinical Practice standards ¹⁷.

Another major responsibility of CDSCO is regulation of imported drugs and cosmetic products ¹⁶. Imported products undergo registration, documentation review, inspection, and quality assessment before approval for marketing within the country. CDSCO additionally conducts post-marketing surveillance and pharmacovigilance activities to monitor adverse drug reactions and ensure continued product safety after commercialization ⁹.

The organization also establishes standards and guidelines related to manufacturing practices, labeling requirements, packaging specifications, licensing procedures, and quality assurance systems associated with pharmaceutical and cosmetic products ¹². CDSCO promotes implementation of Good Manufacturing Practices (GMP) to maintain consistency in product quality and minimize risks associated with contamination and substandard products ¹¹.

Role of Drug Controller General of India (DCGI): The Drug Controller General of India (DCGI) functions as the head of CDSCO and is responsible for approval of new drugs, vaccines, biotechnology products, medical devices, and clinical trials in India ¹⁵. DCGI supervises implementation of regulatory activities associated with pharmaceutical and cosmetic products and ensures uniform enforcement of provisions established under the Drugs and Cosmetics Act and Rules throughout the country ⁶.

The office of DCGI also plays an important role in implementation of regulatory reforms, strengthening pharmacovigilance systems, and harmonization of Indian regulations with international standards ¹². During public health emergencies and pandemics, DCGI is additionally responsible for granting emergency approvals and accelerating review procedures for vaccines and essential healthcare products ¹⁰.

CDSCO in Drug Approval and Monitoring: CDSCO plays a major role in the drug approval process in India by evaluating safety, efficacy, and quality data submitted by pharmaceutical manufacturers ⁵. Approval procedures involve assessment of preclinical studies, clinical trial data, manufacturing information, and quality documentation before marketing authorization is granted ¹⁷. CDSCO also monitors approved products through post-marketing surveillance programs and pharmacovigilance activities to identify adverse drug reactions and ensure continued product safety ⁹.

The organization has introduced several digital initiatives and online licensing systems to improve transparency, efficiency, and accessibility of regulatory services ¹². Regulatory reforms introduced by CDSCO have also strengthened inspection mechanisms, quality assurance systems, and compliance monitoring associated with pharmaceutical industries in India ¹³.

Role of CDSCO in Cosmetic Regulation: CDSCO plays an important role in regulation of cosmetic products by ensuring compliance with safety standards, labeling requirements, manufacturing guidelines, and import regulations ³. The implementation of Cosmetic Rules 2020 established a separate and comprehensive regulatory framework specifically for cosmetic products under the supervision of CDSCO ¹⁴. These rules include guidelines related to cosmetic manufacturing, import registration, packaging specifications, safety evaluation, and quality control measures ¹⁴. CDSCO also monitors cosmetic products for the presence of harmful substances, misleading claims, and non-compliance with prescribed standards

Regulatory Policy in India:

Pharmaceutical Regulatory Policies: Pharmaceutical regulatory policies in India are formulated to ensure that drugs and healthcare products available in the market are safe, effective, and of acceptable quality ⁵. These policies provide a regulatory framework for drug development, manufacturing, import, export, distribution, marketing, and post-marketing surveillance activities associated with pharmaceutical products ⁶. The Indian pharmaceutical regulatory system mainly operates under the provisions of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945, which establish legal standards for pharmaceutical regulation in the country ⁶.

The Ministry of Health and Family Welfare along with CDSCO is responsible for implementation and enforcement of pharmaceutical regulatory policies in India ¹³. Regulatory policies are continuously updated to address advancements in pharmaceutical technology, biotechnology products, clinical research, and pharmacovigilance systems ¹². These policies also aim to improve accessibility of essential medicines while maintaining public health protection and quality assurance standards ¹⁰.

Objectives of Regulatory Policies: The primary objective of pharmaceutical regulatory policies is to safeguard public health by ensuring the safety, efficacy, and quality of pharmaceutical products marketed within the country ⁸. Regulatory policies are intended to prevent manufacture and distribution of counterfeit, adulterated, misbranded, and substandard drugs that may create risks for consumers ⁷.

Another important objective is to establish uniform standards related to manufacturing practices, licensing procedures, labeling requirements, packaging specifications, and quality control systems ⁵. Regulatory policies also support ethical conduct of clinical trials, monitoring of adverse drug reactions, and implementation of pharmacovigilance programs for continuous safety assessment of marketed drugs ^9. In addition, pharmaceutical regulations facilitate international trade by promoting compliance with global standards established by WHO and ICH guidelines ¹¹.

Drug Approval and Regulatory Pathways: Drug approval in India involves a systematic regulatory pathway designed to evaluate the safety, efficacy, and quality of pharmaceutical products before marketing authorization is granted ¹⁸. Pharmaceutical companies are required to submit detailed documentation including preclinical data, clinical trial results, manufacturing information, quality control reports, and labeling details to CDSCO for regulatory evaluation ⁵.

The approval process generally includes preclinical studies, clinical trial authorization, review of clinical data, inspection of manufacturing facilities, and final regulatory assessment before approval of the product ¹⁷. CDSCO also regulates approval pathways for biological products, vaccines, biosimilars, and medical devices in accordance with established regulatory guidelines ¹². Accelerated approval procedures and emergency authorization pathways may be implemented during public health emergencies to improve availability of essential healthcare products ¹⁰.

Regulatory Compliance Requirements: Regulatory compliance is an essential aspect of pharmaceutical industries to ensure adherence to established legal and scientific standards throughout the product lifecycle ⁵. Pharmaceutical manufacturers are required to comply with Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and Good Clinical Practices (GCP) to maintain product quality, consistency, and patient safety ¹¹.

Compliance requirements also include maintenance of documentation systems, validation procedures, quality assurance activities, pharmacovigilance reporting, and implementation of standard operating procedures during manufacturing and distribution processes ⁹. Regulatory authorities conduct inspections and audits to evaluate compliance status of pharmaceutical manufacturing facilities and ensure adherence to regulatory guidelines ¹³. Non-compliance with regulatory provisions may result in penalties, suspension of licenses, product recalls, or legal actions against manufacturers ⁶.

Recent Regulatory Reforms in India: The Indian pharmaceutical regulatory framework has undergone several reforms in recent years to strengthen healthcare safety systems and harmonize with international standards ¹². Regulatory reforms have focused on modernization of licensing procedures, implementation of online submission systems, strengthening pharmacovigilance programs, and improving transparency in drug approval processes ¹³.

The introduction of New Drugs and Clinical Trials Rules, 2019 represented a major regulatory advancement aimed at improving efficiency in clinical trial approval and promoting innovation within the pharmaceutical sector ¹⁸. Similarly, implementation of Cosmetic Rules 2020 established separate regulatory provisions for cosmetic products and strengthened quality assurance mechanisms associated with cosmetic manufacturing and import ¹⁴.

Digitalization of regulatory systems, online licensing platforms, and risk-based inspection strategies have further improved efficiency and accessibility of regulatory services in India ¹².

Certificate of Pharmaceutical Product (COPP):

Introduction to COPP: Certificate of Pharmaceutical Product (COPP) is an official document issued by regulatory authorities to certify the quality, safety, and regulatory status of pharmaceutical products intended for export.¹⁹ The certificate is mainly issued in accordance with the World Health Organization (WHO) Certification Scheme for pharmaceutical products moving in international commerce ¹⁰. COPP serves as evidence that the pharmaceutical product is authorized for marketing in the exporting country and is manufactured according to approved quality standards and Good Manufacturing Practices (GMP) ¹¹.

The certificate is widely used by importing countries to evaluate the authenticity and regulatory status of pharmaceutical products before granting marketing authorization or import approval ²⁰. In India, COPP is issued by the Central Drugs Standard Control Organization (CDSCO) and other authorized regulatory authorities for pharmaceutical products intended for export to foreign markets ¹³.

WHO Certification Scheme: The WHO Certification Scheme was developed to facilitate international trade of pharmaceutical products and improve confidence regarding the quality and safety of exported medicines ²⁰. The scheme provides a standardized format for exchange of regulatory information between exporting and importing countries related to pharmaceutical products ¹⁰. Under this scheme, regulatory authorities certify that the pharmaceutical product is authorized for sale within the exporting country and is manufactured according to established GMP standards ¹¹. The WHO Certification: Scheme also supports international harmonization of pharmaceutical regulations and helps importing countries assess the reliability of exported pharmaceutical products ²⁰.

Importance of COPP in Pharmaceutical Export: COPP plays a significant role in pharmaceutical export because it serves as proof of regulatory approval and product quality compliance ¹⁹. Many countries require submission of COPP before permitting import or marketing of pharmaceutical products within their territories ²⁰. The certificate enhances international acceptance of pharmaceutical products and improves credibility of manufacturers in global markets ¹³. COPP also facilitates smoother export procedures by providing assurance regarding manufacturing standards, licensing status, and quality compliance of pharmaceutical products ¹¹. In addition, the certificate supports regulatory transparency and helps importing authorities verify the authenticity of pharmaceutical manufacturers and exported products ¹⁰.

Procedure for Obtaining COPP: Manufacturers intending to export pharmaceutical products are required to submit an application to CDSCO or designated licensing authorities for issuance of COPP ¹³. The application generally includes details related to manufacturing licenses, GMP certification, product approval status, product composition, labeling information, and export documentation ²¹.

Regulatory authorities evaluate the submitted documents and may conduct inspections of manufacturing facilities to verify compliance with GMP requirements before issuing the certificate ¹¹. After successful evaluation, COPP is issued in the prescribed format according to WHO Certification Scheme guidelines ²⁰. The certificate remains valid for a specified period and may require renewal depending on importing country requirements ²¹.

Regulatory Importance of COPP: COPP is considered an important regulatory document because it promotes international confidence in pharmaceutical products exported from India and supports implementation of quality assurance systems ¹⁹. The certificate encourages pharmaceutical manufacturers to maintain GMP compliance and regulatory standards during manufacturing and export activities ¹¹.

The increasing globalization of pharmaceutical industries has further enhanced the regulatory importance of COPP in international trade and export authorization processes ²⁰. Regulatory authorities continuously focus on strengthening export certification systems to improve global acceptance of Indian pharmaceutical products and ensure compliance with international regulatory requirements ¹².

Practical Details of COPP: In India, COPP is issued by CDSCO under the authority of the Drug Controller General of India (DCGI) ¹⁵. It is issued in accordance with the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce, which provides a standardized format for exchange of regulatory information between exporting and importing countries ²⁰. Documents required for obtaining COPP include valid manufacturing license, GMP compliance certificate, product marketing authorization, product composition details, Certificate of Analysis of recent batches, and labeling information ²¹.

COPP is generally valid for one to three years depending on importing country requirements and must be renewed before expiry ²¹. It is used in export registration as mandatory proof that the product is approved and GMP-compliant in the country of manufacture ¹⁹. COPP also supports batch traceability by linking exported products to approved manufacturing sites and verified quality standards ²⁰. Analytical methods used for testing exported products must be validated as per ICH Q2(R1) guidelines covering accuracy, precision, specificity, linearity, and robustness before COPP issuance ²⁵.

Certificate of Analysis (COA):

Definition of COA: Certificate of Analysis (COA) is an official quality control document issued by the manufacturer or authorized analytical laboratory to certify that a pharmaceutical or cosmetic product complies with predetermined specifications and quality standards ²². The certificate contains analytical results obtained during testing of raw materials, intermediate products, and finished formulations to ensure product quality, purity, strength, and safety before release into the market ²³.

COA is considered an important regulatory and quality assurance document within pharmaceutical and cosmetic industries because it provides documented evidence regarding compliance of products with approved standards and specifications ¹⁹. Regulatory authorities and importing agencies frequently require COA during product approval, export procedures, and quality verification processes ²¹.

Components of COA: A standard Certificate of Analysis generally contains detailed information related to product identification, batch number, manufacturing date, expiry date, specification limits, analytical methods, and test results ²⁴. The document may also include parameters such as appearance, assay, dissolution, microbial limits, impurity profile, pH, and stability data depending on the nature of the product ²³. In addition, COA contains signatures of authorized quality control personnel and certification statements confirming that the product complies with established standards and regulatory requirements ²². Proper documentation and maintenance of COA are essential for ensuring traceability and accountability within pharmaceutical and cosmetic manufacturing systems ¹¹.

Importance of COA in Quality Assurance: COA plays a significant role in quality assurance by providing evidence that pharmaceutical and cosmetic products have undergone required analytical testing and comply with approved quality specifications ²³. The certificate helps manufacturers maintain consistency in product quality and supports implementation of Good Manufacturing Practices (GMP) within manufacturing facilities ¹¹.

COA also contributes toward prevention of distribution of substandard, contaminated, or adulterated products by verifying compliance with quality standards before product release ²². Regulatory authorities, distributors, healthcare institutions, and importing agencies use COA as a quality verification tool during procurement, inspection, and regulatory evaluation processes ²¹.

Role of COA in Regulatory Compliance: Regulatory authorities require submission of COA as part of documentation associated with product approval, licensing, import-export procedures, and quality audits ²⁴. The certificate serves as documented proof that pharmaceutical and cosmetic products comply with established pharmacopeial standards and regulatory requirements ²³.

COA also supports Pharmacovigilance and quality monitoring activities by maintaining accurate records related to analytical testing and product specifications ¹². During inspections and regulatory audits, manufacturers are required to maintain updated COA records for verification of compliance with quality assurance systems and manufacturing standards ¹¹.

Documentation and Validation Requirements: Proper documentation and validation are essential components associated with preparation and maintenance of Certificate of Analysis ²⁴. Analytical methods used for testing pharmaceutical and cosmetic products should be validated according to regulatory guidelines to ensure accuracy, precision, reproducibility, and reliability of analytical results ²⁵.

Manufacturers are required to maintain standardized documentation systems, calibration records, analytical reports, and batch manufacturing records to support information provided in COA ²³. Regulatory authorities may inspect these records during audits and quality assessments to verify compliance with Good Manufacturing Practices and regulatory standards ⁵. Proper documentation and validation practices therefore contribute significantly toward product quality assurance and regulatory compliance within pharmaceutical and cosmetic industries ²².

Practical Details of COA: COA is issued by the manufacturer or an accredited analytical laboratory and is required during regulatory submissions, import-export procedures, and quality audits ²². All analytical methods referenced in COA must be validated according to ICH Q2(R1) guidelines to ensure that results are scientifically reliable and reproducible ²⁵. Each COA must be linked to a specific batch manufacturing record, raw material COAs, in-process control records, and finished product testing reports to ensure complete batch traceability from raw material sourcing to final product release ²³. Importing countries and regulatory agencies including CDSCO and WHO prequalification programs require COA as part of shipment documentation and product registration dossiers ²⁰. Failure to provide a valid and properly authorized COA may result in rejection of shipments or regulatory penalties ²⁴.

Export and Import Licensing:

Import License Requirements: Import licensing is an important regulatory mechanism used to ensure that pharmaceutical and cosmetic products entering the country comply with prescribed standards of safety, quality, and efficacy ⁶. In India, import of drugs and cosmetics is regulated under the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 ²⁶. Importers are required to obtain appropriate licenses and registrations from the Central Drugs Standard Control Organization (CDSCO) before importing pharmaceutical or cosmetic products into the country ¹³.

The application process for import licensing generally includes submission of product details, manufacturing information, Free Sale Certificate, Good Manufacturing Practice (GMP) certification, labeling information, and supporting regulatory documents ²¹. Imported products may also undergo inspection and quality evaluation before approval for distribution within the country ²⁴.

Export License Procedures: Export licensing procedures are intended to ensure that pharmaceutical products exported from India comply with regulatory standards and quality requirements specified by importing countries ¹⁹. Manufacturers intending to export pharmaceutical products are required to obtain export certification and relevant regulatory approvals from authorized authorities ²¹. Export procedures generally involve submission of manufacturing licenses, Certificate of Pharmaceutical Product (COPP), Certificate of Analysis (COA), product specifications, and labeling information ²². Regulatory authorities may inspect manufacturing facilities to verify compliance with Good Manufacturing Practices before issuing export approvals ¹¹. Export certification plays an important role in improving international acceptance and credibility of Indian pharmaceutical products in global markets ¹⁹.

Documentation Required for Import and Export: Proper documentation is essential during import and export of pharmaceutical and cosmetic products to ensure regulatory compliance and product traceability ²⁶. Commonly required documents include manufacturing licenses, import-export licenses, invoices, packing lists, Certificate of Analysis, Certificate of Pharmaceutical Product, batch records, and labeling information ²².

Additional documents such as GMP certificates, Free Sale Certificates, product registration certificates, and shipping details may also be required depending on the regulatory requirements of importing countries ²¹. Accurate documentation helps regulatory authorities verify authenticity, quality compliance, and legal status of pharmaceutical and cosmetic products involved in international trade ²⁰.

Labeling and Packaging Requirements: Labeling and packaging requirements are important regulatory components associated with import and export of pharmaceutical and cosmetic products ²⁷. Labels should contain essential information such as product name, batch number, manufacturing date, expiry date, storage conditions, manufacturer details, and usage instructions according to regulatory guidelines ⁶.

Packaging systems should ensure protection of products from contamination, environmental damage, and physical deterioration during transportation and storage ¹¹. Regulatory authorities monitor labeling and packaging compliance to prevent misleading claims, incorrect information, and distribution of unsafe products within the market ¹³. Regulatory Authorities Involved Several regulatory authorities are involved in monitoring and controlling import and export activities associated with pharmaceutical and cosmetic products in India. CDSCO acts as the primary authority responsible for granting approvals and ensuring regulatory compliance related to imported and exported healthcare products ¹³.

Other authorities including customs departments, port offices, Directorate General of Foreign Trade (DGFT), and State Drug Control Authorities also participate in inspection, documentation review, and monitoring of import-export procedures ²⁶. Coordination among these regulatory bodies is essential for maintaining product quality, consumer safety, and legal compliance during international trade activities ¹².

Challenges in Import and Export Regulation: Despite implementation of regulatory systems, several challenges continue to affect import and export regulation of pharmaceutical and cosmetic products ⁷. Variations in international regulatory requirements, documentation complexities, counterfeit products, delays in approval procedures, and lack of harmonization among global regulatory systems create significant difficulties for manufacturers and exporters ¹⁰.

Continuous regulatory reforms and modernization of import-export procedures are therefore necessary to improve efficiency, transparency, and global competitiveness of Indian pharmaceutical and cosmetic industries ¹².

Cosmetic Rules 2020:

Overview of Cosmetic Rules 2020: Cosmetic Rules 2020 were introduced by the Ministry of Health and Family Welfare, Government of India, to establish a separate and comprehensive regulatory framework for cosmetics manufactured, imported, and marketed in India ¹⁴. The rules were implemented under the provisions of the Drugs and Cosmetics Act, 1940 with the objective of strengthening regulation, improving product safety, and ensuring quality compliance within the cosmetic industry ³.

Prior to implementation of Cosmetic Rules 2020, cosmetic products were regulated under provisions mainly designed for pharmaceuticals, which created limitations in addressing cosmetic-specific regulatory requirements ¹². The introduction of separate cosmetic rules therefore represented a significant advancement in Indian cosmetic regulation by providing dedicated guidelines for licensing, labeling, manufacturing, import registration, inspection, and quality control of cosmetic products ²⁹.

Objectives and Scope: The primary objective of Cosmetic Rules 2020 is to ensure that cosmetic products available in the market are safe, effective, and manufactured according to prescribed quality standards ³. The rules aim to regulate import, manufacture, distribution, labeling, packaging, and sale of cosmetic products while protecting consumers from unsafe or misleading products ¹⁴. The scope of Cosmetic Rules 2020 includes regulation of cosmetic manufacturing units, importers, testing laboratories, and licensing procedures associated with cosmetic products.²⁹ The rules also define responsibilities of manufacturers and regulatory authorities in maintaining product safety and compliance with established standards ¹².

Licensing Provisions under Cosmetic Rules: Cosmetic Rules 2020 introduced a structured licensing system for cosmetic manufacturing and import activities in India ¹⁴. Manufacturers are required to obtain appropriate licenses before commencing production or distribution of cosmetic products ³⁰. Licensing procedures involve submission of application forms, manufacturing details, product specifications, and compliance documents to the licensing authority ²⁹. The rules also include provisions related to loan licenses, additional product permissions, and renewal of licenses for cosmetic manufacturing units ³. Regulatory authorities may conduct inspections of manufacturing facilities before granting approvals to ensure compliance with prescribed standards and Good Manufacturing Practices ¹¹.

Manufacturing Requirements: Manufacturing requirements under Cosmetic Rules 2020 are intended to ensure production of safe and quality cosmetic products under hygienic conditions ¹¹. Cosmetic manufacturers are required to maintain suitable infrastructure, qualified technical staff, sanitation measures, equipment maintenance, and quality control systems during manufacturing operations ³¹.

Manufacturing units should comply with Good Manufacturing Practices (GMP) and maintain proper documentation related to raw materials, batch processing, testing procedures, and product distribution ¹². These requirements help in minimizing contamination risks, maintaining product consistency, and ensuring consumer safety ¹¹.

Safety and Quality Requirements: Safety and quality requirements under Cosmetic Rules 2020 are designed to ensure that cosmetic products do not cause harm to consumers under normal conditions of use ³. Cosmetic products should not contain prohibited or harmful substances beyond prescribed limits and must comply with established safety standards ¹⁴.

Manufacturers are responsible for conducting appropriate quality control testing and maintaining records related to product safety and stability evaluation ¹³. Regulatory authorities may inspect cosmetic products and manufacturing facilities to verify compliance with safety and quality requirements ¹³.

Labeling and Packaging Requirements: Labeling and packaging requirements are important regulatory components under Cosmetic Rules 2020. Labels should contain essential information including product name, manufacturer details, batch number, manufacturing date, expiry date, ingredients, and directions for use ²⁷. Misleading claims and false information on cosmetic labels are prohibited under the rules ³. Packaging systems should provide adequate protection against contamination, leakage, and deterioration of cosmetic products during storage and transportation ¹¹. Proper labeling and packaging help consumers identify products correctly and improve product traceability within the market ²⁹.

Inspection and Compliance Requirements: Regulatory authorities are authorized to conduct inspections of cosmetic manufacturing units, warehouses, and distribution facilities to evaluate compliance with Cosmetic Rules 2020 ¹³. Inspections generally include assessment of manufacturing conditions, documentation systems, sanitation measures, quality control procedures, and labeling practices ³¹.

Manufacturers are required to maintain records related to production, testing, complaints, and distribution for verification during inspections and audits ¹¹. Non-compliance with prescribed regulatory provisions may result in suspension or cancellation of licenses, penalties, or legal actions against manufacturers ⁶.

Recent Amendments and Updates: Several amendments and updates have been introduced under Cosmetic Rules 2020 to improve regulatory efficiency and harmonize Indian cosmetic regulations with international standards.¹² Digitalization of licensing procedures, online application systems, and risk-based inspection mechanisms have improved transparency and accessibility of regulatory services ¹³.

Continuous regulatory reforms are being implemented to strengthen consumer protection, improve cosmetic safety monitoring, and enhance quality assurance practices within the cosmetic industry ³². Increasing globalization of cosmetic markets has further highlighted the importance of harmonization of Indian cosmetic regulations with international regulatory guidelines and quality standards ¹¹.

Drugs and Cosmetics Act and Rules:

Historical Background: The Drugs and Cosmetics Act, 1940 was enacted by the Government of India to regulate the import, manufacture, distribution, and sale of drugs and cosmetics throughout the country ⁶. The Act was introduced mainly to prevent circulation of substandard, adulterated, and misbranded pharmaceutical and cosmetic products and to ensure protection of public health ⁵. Before implementation of the Act, India lacked a uniform regulatory system capable of controlling the quality and safety of healthcare products available in the market ¹².

Over the years, several amendments have been incorporated into the Drugs and Cosmetics Act and Rules to address advancements in pharmaceutical technology, clinical research, biotechnology products, cosmetic regulation, and international regulatory harmonization ³³. These amendments have strengthened regulatory control and improved quality assurance systems associated with pharmaceutical and cosmetic industries in India ¹¹.

Objectives of the Act: The major objective of the Drugs and Cosmetics Act is to ensure that pharmaceutical and cosmetic products marketed within the country comply with prescribed standards of safety, efficacy, and quality ⁶. The Act aims to regulate manufacturing practices, licensing procedures, import-export activities, labeling requirements, and quality control systems associated with drugs and cosmetics ⁵.

Another important objective of the Act is prevention of manufacture and distribution of adulterated, counterfeit, spurious, and substandard products that may create risks for consumers ⁷. The Act also supports implementation of regulatory inspections, product testing, pharmacovigilance activities, and legal actions against manufacturers involved in regulatory violations ¹³.

Important Provisions Under the Act: The Drugs and Cosmetics Act contains several provisions related to licensing, manufacturing, distribution, labeling, packaging, testing, and sale of pharmaceutical and cosmetic products ⁶. The Act authorizes CDSCO and State Drug Control Authorities to monitor compliance with regulatory requirements and conduct inspections of manufacturing and distribution facilities ¹³.

Important provisions under the Act include regulation of new drug approval, clinical trial authorization, import registration, quality control testing, GMP implementation, and post marketing surveillance systems ¹⁸. The Act also includes provisions associated with storage conditions, documentation requirements, and recall procedures for defective products ¹¹.

Classification of Drugs and Cosmetics: Under the Drugs and Cosmetics Act, pharmaceutical products are classified according to their therapeutic use, composition, and regulatory requirements ³⁴. The Act includes provisions related to prescription drugs, over-the-counter products, biological products, vaccines, medical devices, and cosmetic preparations ¹².

Cosmetic products are regulated separately under Cosmetic Rules 2020 and include products intended for cleansing, beautifying, promoting attractiveness, or altering appearance without affecting body structure or physiological functions ¹⁴. Classification of products helps regulatory authorities determine licensing requirements, manufacturing standards, and quality control procedures applicable to specific product categories ²⁹.

Offences and Penalties: The Drugs and Cosmetics Act contains provisions related to offences and penalties associated with manufacture or distribution of adulterated, spurious, counterfeit, or misbranded pharmaceutical and cosmetic products ⁶. Manufacturers violating regulatory provisions may face suspension or cancellation of licenses, financial penalties, product recalls, and legal prosecution ⁷.

Stringent penalties have been introduced to discourage illegal manufacturing practices and improve regulatory compliance within pharmaceutical and cosmetic industries ³³.

Regulatory authorities are also empowered to conduct investigations, seize non-compliant products, and initiate legal actions against individuals or organizations involved in regulatory violations ¹³.

Amendments and Recent Developments: Several amendments and reforms have been introduced under the Drugs and Cosmetics Act and Rules to strengthen pharmaceutical and cosmetic regulation in India ¹². Recent developments include implementation of New Drugs and Clinical Trials Rules, 2019, Cosmetic Rules 2020, digital licensing systems, pharmacovigilance strengthening programs, and risk-based inspection mechanisms ¹⁸.

Increasing globalization of pharmaceutical trade and rapid technological advancements have further emphasized the need for modernization and harmonization of Indian regulations with international standards established by WHO and ICH ¹¹. Continuous amendments therefore remain essential for improving healthcare safety, regulatory efficiency, and quality assurance systems associated with pharmaceutical and cosmetic products ³⁵.

Regulatory forms under Cosmetic Rules:

Form COS-5: Application for Manufacturing Licence: Form COS-5 is the prescribed application form for obtaining a licence to manufacture cosmetic products for sale or distribution under the Cosmetics Rules, 2020. The application is submitted to the State Licensing Authority along with the prescribed fee and supporting documents. Applicants are required to provide details of manufacturing premises, plant layout, machinery and equipment, technical personnel, quality control facilities, and product-related information. The application is evaluated to ensure compliance with regulatory requirements and Good Manufacturing Practices (GMP) before grant of a manufacturing licence ¹⁴.

Form COS-6: Application for Loan Licence: Form COS-6 is used for applying for a loan licence to manufacture cosmetics using the manufacturing facilities of another licensed manufacturer. The applicant must furnish details regarding contractual manufacturing arrangements, quality control systems, product categories, technical supervision, and supporting compliance documentation. The State Licensing Authority evaluates the submitted information to ensure compliance with the Cosmetics Rules, 2020 and applicable GMP requirements ²⁹.

Form COS-8: Manufacturing Licence: Form COS-8 is the licence granted by the State Licensing Authority authorizing the manufacture of cosmetic products for sale or distribution. The licence is issued after satisfactory review of the application, verification of supporting documents, and inspection of the manufacturing facility. The licence holder is required to maintain prescribed standards relating to production, quality control, sanitation, documentation, and product safety throughout the period of operation ³⁰.

Form COS-9: Loan Licence: Form COS-9 is the loan licence issued to applicants who manufacture cosmetic products using the facilities of another licensed manufacturer. The licence is granted after assessment of manufacturing arrangements and compliance with applicable regulatory requirements. Holders of a loan licence are required to maintain adequate quality assurance systems and ensure that products are manufactured in accordance with approved specifications and regulatory standards ¹⁴.

Licensing Authority and Supporting Documents: The State Licensing Authority is responsible for granting, retaining, suspending, or cancelling cosmetic manufacturing licences and loan licences. Applications should be accompanied by supporting documents including details of premises, equipment, technical personnel, quality control facilities, product specifications, labelling particulars, declarations, and prescribed fees. Complete documentation facilitates effective regulatory review and compliance assessment ¹³.

Procedure for Application and Approval: Applications for manufacturing licences and loan licences should be submitted in the prescribed forms together with the required documents and applicable fees. The Licensing Authority may conduct inspections of manufacturing facilities to assess infrastructure, sanitation, equipment, documentation systems, and quality assurance arrangements. Licences are granted only after satisfactory evaluation of compliance with the Cosmetics Rules, 2020 and Good Manufacturing Practices ³¹.

Validity, Retention and Compliance: Licences issued under the Cosmetics Rules, 2020 remain valid subject to continued compliance with regulatory requirements and payment of prescribed retention fees, wherever applicable. Manufacturers are expected to comply with licence conditions, maintain product quality standards, and preserve relevant records for regulatory review. Failure to comply with statutory requirements may result in suspension or cancellation of the licence by the Licensing Authority ¹⁴.

Regulatory Updates: As regulatory requirements and prescribed forms may be modified through amendments, notifications, and official guidance documents, manufacturers should periodically verify form numbers, licensing procedures, supporting documentation requirements, retention provisions, and compliance obligations against the latest version of the Cosmetics Rules, 2020 and related government notifications ³².

Legal Requirements for Online Sale of Drugs and Cosmetics:

Introduction to E-Pharmacy and Online Cosmetic Sales: Rapid growth of digital technology and e-commerce platforms has significantly increased the online sale of pharmaceutical and cosmetic products in India ³⁸. Online pharmacies and cosmetic retail platforms provide consumers with convenient access to healthcare and personal care products through internet-based services ¹². Increasing internet penetration, digital payment systems, and consumer preference for home delivery services have further accelerated the growth of e-pharmacy and online cosmetic markets ³⁹. Despite the advantages associated with online sales, concerns related to counterfeit medicines, inappropriate dispensing practices, misuse of prescription drugs, and sale of unregulated cosmetic products have created major regulatory challenges.⁷ Therefore, implementation of effective legal and regulatory frameworks is essential to ensure consumer safety and quality assurance in online pharmaceutical and cosmetic trade ⁶.

Legal Framework Governing Online Sales: The online sale of drugs in India is presently governed through provisions of the Drugs and Cosmetics Act, 1940, Drugs and Cosmetics Rules, 1945, Information Technology Act, 2000, and other applicable consumer protection and e-commerce regulations ³⁹. However, a comprehensive and dedicated e-pharmacy regulatory framework has not yet been formally notified. Drafte-pharmacy rules and guidelines have been proposed by regulatory authorities, but these are not currently enforceable as final legislation. Therefore, online pharmacies operate under existing legal provisions while regulatory authorities continue to evaluate the need for a separate framework ⁴⁰.

Registration and Licensing Requirements: Online pharmacies and cosmetic sale platforms are required to comply with licensing and registration requirements prescribed by regulatory authorities.³⁸ E-pharmacy operators must obtain licenses from appropriate authorities and ensure that pharmaceutical products are dispensed only against valid prescriptions issued by registered medical practitioners ⁴⁰.

Licensing requirements also include maintenance of proper storage facilities, appointment of qualified pharmacists, documentation systems, and mechanisms for consumer grievance redressal ¹¹. Online cosmetic retailers are similarly expected to ensure that products sold through digital platforms comply with labeling, safety, and quality requirements established under Cosmetic Rules 2020 ¹⁴.

Consumer Protection and Safety: Consumer protection is an important aspect associated with regulation of online sale of pharmaceutical and cosmetic products. Regulatory authorities monitor online platforms to prevent circulation of counterfeit medicines, expired products, spurious cosmetics, and misleading advertisements ⁷. Online pharmacies are required to maintain confidentiality of patient information, ensure secure digital transactions, and provide accurate product-related information to consumers ³⁹. Regulatory authorities may take legal action against online platforms involved in unauthorized sale of prescription medicines or distribution of non-compliant cosmetic products ⁶.

Challenges in Online Drug and Cosmetic Regulation: Practical enforcement challenges include verification of prescriptions, monitoring interstate and cross-border sales, prevention of counterfeit products, protection of patient data, and effective surveillance of digital platforms. These challenges highlight the need for stronger regulatory coordination and clearer legal provisions for e-pharmacy operations ⁴⁰.

Future Regulatory Perspectives for E-Pharmacy: Future regulatory reforms associated with e-pharmacy and online cosmetic sales should focus on strengthening digital monitoring systems, implementation of centralized online licensing platforms, and harmonization of regulatory guidelines across different states ⁴⁰.

Use of artificial intelligence, digital prescription verification systems, and block chain-based traceability mechanisms may improve transparency and regulatory efficiency associated with online pharmaceutical trade ¹¹.

Continuous updating of legal frameworks and stricter enforcement of online sale regulations are essential to improve consumer safety, prevent misuse of medicines, and ensure quality assurance of pharmaceutical and cosmetic products sold through digital platforms ³⁸.

Good Manufacturing Practices (GMP):

Introduction to GMP: Good Manufacturing Practices (GMP) are regulatory guidelines designed to ensure that pharmaceutical and cosmetic products are consistently manufactured and controlled according to established quality standards ¹¹. GMP forms an essential component of quality assurance systems within pharmaceutical and cosmetic industries because it minimizes risks associated with contamination, cross-contamination, product mix-ups, and manufacturing errors ²³.

Implementation of GMP is necessary to ensure safety, efficacy, purity, and consistency of healthcare products before they reach consumers ⁶. Regulatory authorities including CDSCO and WHO emphasize strict adherence to GMP requirements during manufacturing, packaging, labeling, storage, and distribution activities associated with pharmaceutical and cosmetic products ¹³.

Objectives of GMP: The primary objectives of GMP include prevention of contamination, maintenance of product consistency, implementation of quality assurance systems, and protection of consumer health ²³. GMP guidelines ensure that products are manufactured under hygienic conditions using validated procedures and properly maintained equipment ²⁵. Another important objective of GMP is maintenance of standardized documentation systems associated with manufacturing, testing, packaging, and distribution activities ¹¹. GMP also helps manufacturers comply with regulatory requirements and facilitates international acceptance of pharmaceutical and cosmetic products in global markets ²⁰.

Schedule M Requirements: Schedule M under the Drugs and Cosmetics Rules, 1945 specifies Good Manufacturing Practice (GMP) requirements for pharmaceutical manufacturing facilities ⁴¹. Recent revisions emphasize a Pharmaceutical Quality System (PQS), Quality Risk Management (QRM), qualification and validation activities, data integrity, change control, deviation management, complaint handling, product recall procedures, and self-inspection programs.

Premises and Facilities: Manufacturing areas should be properly designed, maintained, and sanitized to prevent contamination and cross-contamination ²³.

Equipment: Equipment must be qualified, calibrated, maintained, and cleaned according to approved procedures ²³.

Quality Risk Management: Manufacturers should identify, assess, control, and review risks that may affect product quality ⁴².

Validation: Manufacturing processes, cleaning procedures, analytical methods, and computerized systems should be validated and documented ²⁵.

Documentation and Data Integrity: Records should be accurate, complete, contemporaneous, attributable, and readily retrievable throughout the product lifecycle ⁴².

Complaints and Product Recall: Procedures should be established for investigation of complaints and efficient recall of defective products from the market ²⁴.

Self-Inspection: Periodic self-inspections should be conducted to evaluate compliance with GMP requirements and identify opportunities for continuous improvement ²³.

GMP Requirements for Pharmaceutical Industries Pharmaceutical industries are required to maintain hygienic manufacturing conditions, qualified personnel, validated manufacturing procedures, and effective quality assurance systems according to GMP guidelines ²³. Manufacturing areas should be designed to minimize contamination and cross-contamination during production processes ⁴¹. Personnel involved in manufacturing operations should receive appropriate training related to hygiene practices, equipment handling, documentation procedures, and quality control systems ¹¹. Manufacturers are also required to maintain standard operating procedures (SOPs), calibration records, validation reports, and batch manufacturing documentation for regulatory verification ²⁵.

GMP Requirements for Cosmetic Industries: Cosmetic industries are similarly required to comply with GMP requirements to ensure safety and quality of cosmetic products ¹⁴. Cosmetic manufacturing units should maintain suitable infrastructure, sanitation measures, equipment maintenance systems, and quality control procedures according to prescribed standards ³¹.

Raw materials, packaging materials, and finished cosmetic products should be stored under appropriate conditions to prevent contamination and deterioration ²³. Cosmetic manufacturers are also expected to maintain documentation systems related to production activities, testing procedures, complaints, and product recalls ¹¹.

Documentation and Record Maintenance: Documentation and record maintenance constitute important components of GMP because they ensure traceability, accountability, and regulatory compliance throughout manufacturing operations ²⁵. Manufacturers are required to maintain batch manufacturing records, analytical reports, equipment maintenance logs, validation reports, calibration records, and distribution records according to GMP guidelines ⁴².

Proper documentation helps regulatory authorities evaluate manufacturing consistency and quality assurance systems during inspections and audits ¹³. Inadequate documentation practices may result in regulatory non-compliance, product recalls, or legal actions against manufacturers ⁶.

Quality Assurance and Quality Control: Quality assurance and quality control systems are essential for ensuring consistency, safety, and effectiveness of pharmaceutical and cosmetic products ²³. Quality assurance focuses on implementation of systematic procedures to prevent quality defects, while quality control involves analytical testing and evaluation of raw materials, intermediate products, and finished formulations ²². Quality control laboratories are responsible for conducting tests related to assay, dissolution, microbial limits, impurity profile, and stability evaluation according to approved specifications ²⁵. Effective quality assurance and quality control systems therefore contribute significantly toward regulatory compliance and consumer protection ¹¹.

Regulatory Inspection and Compliance: Regulatory authorities conduct inspections and audits of pharmaceutical and cosmetic manufacturing facilities to evaluate compliance with GMP requirements and regulatory standards ¹³. Inspections generally involve assessment of manufacturing conditions, sanitation systems, documentation practices, equipment maintenance, quality control procedures, and employee training programs ⁴¹.

Manufacturers failing to comply with GMP requirements may face suspension or cancellation of licenses, product recalls, warning notices, financial penalties, or legal actions ⁶. Continuous monitoring and periodic inspections are therefore essential for maintaining regulatory compliance and ensuring quality assurance within pharmaceutical and cosmetic industries ¹¹.

Regulatory Aspects for Geriatrics and Pediatrics:

Introduction: Pediatric and geriatric populations require special regulatory consideration because of physiological variations, altered pharmacokinetics, dosage differences, and increased susceptibility to adverse drug reactions associated with these patient groups ⁴³. Pharmaceutical products intended for pediatric and geriatric use must therefore undergo careful evaluation regarding safety, efficacy, dosage accuracy, and patient compliance before approval for marketing ¹⁰.

Regulatory authorities emphasize development of age-appropriate dosage forms, appropriate labeling systems, and post-marketing safety monitoring for pediatric and geriatric pharmaceutical products ¹². Increasing prevalence of chronic diseases, poly pharmacy, and age-related physiological changes have further highlighted the importance of specialized regulatory guidelines for these populations ⁴⁴.

Regulatory Requirements for Pediatric Products: Pediatric pharmaceutical products are required to undergo extensive safety and efficacy evaluation because children exhibit physiological characteristics that differ significantly from adults ⁴3. Regulatory authorities require manufacturers to conduct pediatric clinical studies, dose optimization studies, and formulation development activities suitable for different pediatric age groups ¹⁷.

Pediatric formulations should provide accurate dosing, improved palatability, ease of administration, and reduced risk of medication errors ⁴⁴. Liquid dosage forms, dispersible tablets, oral films, and age-appropriate formulations are commonly preferred for pediatric use ⁴⁵. Regulatory guidelines also require inclusion of pediatric-specific labeling information, dosage instructions, contraindications, and safety warnings to ensure appropriate use of medicines in children ¹¹.

Age-Appropriate Formulations: Pediatric products must be developed in age-appropriate dosage forms such as oral liquids, dispersible tablets, oral films, and mini-tablets suitable for different age groups as categorized by ICH E11(R1) ⁴⁵. Excipient safety requires special attention as certain excipients safe in adults may cause serious adverse effects in neonates and young infants ⁴³.

Clinical Trial Ethics: Pediatric clinical trials must follow ethical principles under ICMR National Ethical Guidelines and ICH E11 ¹⁷. Dose optimization using population pharmacokinetic modeling is required to establish safe dosing for different pediatric age groups ⁴³.

Labeling Requirements: Pediatric labels must include age-specific dosage instructions, weight-based dosing, contraindications by age group, and warnings for unsafe excipients in simple language to prevent caregiver dosing errors ⁴⁴.

Medication Errors and Pharmacovigilance: Pediatric patients are at high risk of medication errors due to weight-based dosing and off-label use ⁴³. Risk minimization strategies including dose-measuring devices and unit-dose packaging are required ⁴⁴. Post-marketing pharmacovigilance must systematically collect adverse drug reaction reports specific to pediatric age groups with expedited reporting for serious reactions ⁹.

Regulatory Requirements for Geriatric Products: Geriatric pharmaceutical products require special regulatory attention because elderly patients often experience altered drug absorption, metabolism, distribution, and elimination due to physiological aging processes ⁴³. Elderly patients are also more susceptible to adverse drug reactions, drug-drug interactions, and complications associated with polypharmacy ⁴⁴.

Regulatory authorities therefore emphasize dose adjustment studies, safety monitoring, and evaluation of therapeutic effectiveness in geriatric populations during drug development and approval procedures ¹⁰. Pharmaceutical formulations intended for elderly patients should also consider swallowing difficulties, visual impairment, cognitive limitations, and patient compliance challenges ⁴⁵.

Dose Adjustment: Age-related physiological changes including reduced renal clearance and decreased hepatic metabolism affect drug pharmacokinetics in elderly patients ⁴³. ICH E7 recommends inclusion of elderly patients in clinical trials ⁴⁵. Dose adjustment studies are required for drugs with narrow therapeutic indices or those eliminated through renal or hepatic pathways ⁴⁴.

Special Safety Monitoring: Geriatric labeling must include dose adjustment recommendations based on renal and hepatic function and warnings regarding fall risk, cognitive effects, and drug-disease interactions ⁴⁴. Enhanced Pharma-covigilance and periodic benefit-risk evaluations should be implemented for products widely used in elderly populations ⁹.

Polypharmacy and Medication Errors: Elderly patients commonly receive multiple medications, increasing risk of drug-drug interactions and medication errors ⁴⁴. Dosage forms should addresss wallowing difficulties and cognitive limitations through orally disintegrating tablets, liquid formulations, and large-print labeled packaging ⁴⁵.

Dosage Form and Labeling Considerations: Dosage forms intended for pediatric and geriatric populations should be designed to improve patient compliance, administration convenience, and medication safety ⁴⁵. Pediatric products should include suitable flavoring agents, accurate measuring devices, and child-resistant packaging systems to prevent dosing errors and accidental ingestion ⁴³.

For geriatric populations, dosage forms should be easy to swallow, easy to handle, and clearly labeled with appropriate dosage instructions and warnings ⁴⁴. Labels should contain legible fonts, dosage schedules, storage instructions, contraindications, and safety precautions to improve medication adherence and minimize risks associated with improper use ¹¹.

Safety and Efficacy Evaluation: Safety and efficacy evaluation constitute essential regulatory requirements associated with pediatric and geriatric pharmaceutical products ¹⁰. Clinical  studies should assess pharmacokinetic parameters, therapeutic effectiveness, adverse drug reactions, and dose-response relationships specific to these patient groups ⁴³.

Post-marketing surveillance and pharmacovigilance systems are particularly important for monitoring adverse drug reactions associated with pediatric and geriatric populations because of their increased vulnerability to medication-related complications ⁹. Regulatory authorities therefore encourage continuous safety monitoring and reporting of adverse drug reactions associated with pharmaceutical products used in these populations ¹².

Challenges in Pediatric and Geriatric Regulation: Several challenges continue to affect regulation of pediatric and geriatric pharmaceutical products. Limited clinical trial participation, ethical concerns associated with pediatric research, dosage complexities, and lack of age-appropriate formulations remain major regulatory challenges ⁴³.

In geriatric populations, challenges associated with polypharmacy, multiple comorbidities, cognitive impairment, and medication adherence complicate evaluation of drug safety and therapeutic effectiveness ⁴⁵. In addition, insufficient clinical data and inadequate formulation development for these special populations continue to create regulatory difficulties ⁴⁵.

Continuous research, formulation innovation, and strengthening of regulatory guidelines are therefore necessary to improve healthcare quality and medication safety associated with pediatric and geriatric pharmaceutical products ¹².

RESULTS AND DISCUSSION:

Current Regulatory Status of Pharmaceuticals and Cosmetics in India: The Indian pharmaceutical and cosmetic regulatory framework has undergone substantial advancements in recent years through implementation of updated regulatory policies, strengthening of pharmacovigilance systems, and digitalization of licensing procedures ¹². The implementation of Cosmetic Rules 2020 established a separate regulatory structure for cosmetics and strengthened quality assurance systems associated with cosmetic manufacturing and import activities ¹⁴.

India has also achieved significant progress in pharmaceutical manufacturing and export activities, becoming one of the major global suppliers of generic medicines and vaccines ². However, increasing industrial growth and globalization have simultaneously increased the need for stronger regulatory coordination and harmonization with international standards ³⁵.

Impact of CDSCO on Public Health Protection: CDSCO has played an important role in protecting public health through implementation of drug approval systems, pharmacovigilance programs, quality control measures, and regulatory inspections ¹³. The organization continuously monitors pharmaceutical and cosmetic products marketed within the country to ensure compliance with safety, efficacy, and quality standards ⁸.

Implementation of pharmacovigilance systems has improved identification and reporting of adverse drug reactions, thereby contributing toward safer use of medicines within healthcare systems ⁹. CDSCO has also strengthened import-export monitoring systems and regulatory inspections to minimize circulation of counterfeit and substandard healthcare products ⁷.

Despite these advances, differences in implementation and enforcement practices may affect the consistency of regulatory oversight. Continued strengthening of regulatory systems and monitoring mechanisms may further improve public health protection ⁴⁶.

Significance of Cosmetic Rules 2020 in Regulatory Advancement: Cosmetic Rules 2020 represented a major advancement in Indian cosmetic regulation because the rules introduced separate regulatory provisions specifically designed for cosmetic products ¹⁴. The rules strengthened licensing systems, manufacturing requirements, labeling standards, and quality control procedures associated with cosmetic industries ²⁹.

Implementation of dedicated cosmetic regulations has improved consumer protection and increased accountability among cosmetic manufacturers and importers ³². In addition, digitalization of licensing procedures and inspection mechanisms has enhanced transparency and efficiency within cosmetic regulatory systems ¹².

Regulatory Importance of COPP and COA: Certificate of Pharmaceutical Product (COPP) and Certificate of Analysis (COA) play significant roles in pharmaceutical quality assurance and international trade compliance ¹⁹. COPP serves as evidence regarding regulatory approval and GMP compliance of pharmaceutical products intended for export, while COA provides documented proof of analytical testing and product quality ²².

These regulatory documents improve international acceptance of pharmaceutical products and facilitate export activities by ensuring compliance with global quality standards and regulatory requirements. These documents also support traceability and international regulatory compliance ²⁵.

However, varying documentation requirements across different regulatory jurisdictions may increase the compliance burden on manufacturers, highlighting the need for greater international harmonization and digitalization of certification processes ^{20, 46}.

Challenges in Import, Export, and Online Sales Regulation: Despite implementation of regulatory systems, several challenges continue to affect import-export activities and online sale of pharmaceutical and cosmetic products in India. Variations in international regulatory requirements, documentation complexities, counterfeit products, and delays in approval procedures remain major concerns associated with import-export regulation ²⁸.

Similarly, online sale of pharmaceutical products has introduced challenges related to illegal sale of prescription medicines, inadequate prescription verification, circulation of counterfeit products, and limited monitoring mechanisms ³⁸.

Increasing digitalization and globalization of healthcare trade therefore require stronger regulatory coordination, digital surveillance systems, and harmonized e-pharmacy regulations ⁴⁰.

Role of GMP in Product Quality and Safety: Implementation of Good Manufacturing Practices (GMP) has significantly improved manufacturing quality, contamination control, documentation systems, and regulatory compliance associated with pharmaceutical and cosmetic products ¹¹. GMP guidelines ensure that products are manufactured under hygienic conditions using validated procedures and effective quality assurance systems ²³.

Schedule M requirements and WHO GMP guidelines have strengthened manufacturing standards within Indian pharmaceutical industries and improved global acceptance of Indian pharmaceutical products ⁴¹. Regular inspections and audits conducted by regulatory authorities further contribute toward maintenance of product quality and consumer safety ¹³.

Recent international quality guidelines also emphasize the use of risk-based approaches for identifying and controlling potential quality issues during pharmaceutical manufacturing. Adoption of such approaches may further strengthen GMP compliance and product quality assurance ⁴⁷.

Recent revisions to Schedule M have strengthened GMP requirements by promoting improved documentation practices, quality management systems, and facility standards. However, implementation of these requirements may require additional resources and infrastructure upgrades, particularly for small and medium-sized manufacturers ⁴⁸.

Regulatory Challenges in Pediatric and Geriatric Products: Pediatric and geriatric pharmaceutical products continue to present unique regulatory challenges because of dosage complexities, altered pharmacokinetics, safety concerns, and limited clinical data associated with these populations ⁴³. Development of age-appropriate formulations and implementation of patient-specific labeling systems remain important regulatory priorities ⁴⁵.

In addition, ethical concerns related to pediatric clinical trials and complications associated with polypharmacy in geriatric patients further complicate regulatory evaluation processes ⁴⁴. Strengthening of specialized regulatory guidelines and increased clinical research activities are therefore necessary to improve medication safety and therapeutic effectiveness for these patient groups ¹².

Comparison of Indian Regulatory System with International Guidelines: The Indian pharmaceutical regulatory system has progressively aligned with international standards established by WHO, ICH, USFDA, and EMA ¹¹. Implementation of GMP guidelines, pharmacovigilance programs, quality risk management systems, and clinical trial regulations has improved harmonization of Indian regulations with global regulatory frameworks ³⁵.

However, challenges associated with regulatory infrastructure, inspection frequency, digital monitoring systems, and enforcement mechanisms still exist when compared with highly developed regulatory agencies ¹². Continuous modernization and adoption of internationally harmonized regulatory practices are therefore essential for improving global competitiveness of Indian pharmaceutical and cosmetic industries ¹⁰.

According to WHO benchmarking frameworks, continuous strengthening of regulatory capacity, inspection systems, and quality management practices remains important for achieving higher levels of regulatory maturity. Further improvements in these areas may enhance international confidence in the Indian regulatory system ⁴⁶.

Emerging Trends and Future Reforms in Regulatory Affairs: Emerging trends in regulatory affairs include digitalization of regulatory systems, artificial intelligence-based pharmacovigilance monitoring, block chain-supported supply chain traceability, and implementation of risk-based inspection strategies ⁴⁰.

Future regulatory reforms should focus on strengthening e-pharmacy regulations, improving data integrity systems, enhancing coordination among regulatory authorities, and harmonizing Indian regulations with evolving international standards ¹¹. Adoption of advanced technologies and modernization of regulatory infrastructure will therefore play a major role in improving healthcare quality, product safety, and regulatory efficiency in India ³⁵.

CONCLUSION: The pharmaceutical and cosmetic regulatory framework in India has undergone substantial advancements in recent years through implementation of updated regulatory policies, strengthening of pharmacovigilance systems, adoption of Good Manufacturing Practices (GMP), and introduction of digital regulatory services ¹². Regulatory authorities such as the Central Drugs Standard Control Organization (CDSCO) play a significant role in ensuring that pharmaceutical and cosmetic products marketed within the country comply with prescribed standards of safety, efficacy, and quality ¹³.

Implementation of Cosmetic Rules 2020 has further strengthened cosmetic regulation in India by introducing dedicated provisions related to licensing, labeling, manufacturing, quality assurance, and inspection mechanisms ¹⁴. Regulatory documents such as Certificate of Pharmaceutical Product (COPP) and Certificate of Analysis (COA) have also contributed significantly toward international trade compliance, quality assurance, and global acceptance of Indian pharmaceutical products ¹⁹.

Despite remarkable progress, several challenges including counterfeit medicines, inadequate regulatory enforcement, online sale of drugs, documentation complexities, and harmonization with international standards continue to affect pharmaceutical and cosmetic regulation in India ⁷. In addition, increasing globalization, technological advancements, and expansion of e-pharmacy systems have created new regulatory concerns associated with digital healthcare services and online product distribution ³⁸.

Implementation of stronger monitoring systems, modernization of regulatory infrastructure, adoption of advanced digital technologies, and harmonization with international regulatory guidelines are therefore essential for improving healthcare quality, regulatory efficiency, and consumer safety ¹¹. Continuous reforms and coordinated efforts among regulatory authorities, healthcare professionals, manufacturers, and policymakers will further strengthen the Indian pharmaceutical and cosmetic regulatory framework and enhance its global competitiveness.

ACKNOWLEDGEMENTS: Nil

CONFLICTS OF INTEREST: Nil

REFERENCES:

1. Chatterjee S, Sharma P and Verma R: Current scenario of pharmaceutical industries and regulatory bodies in India. Int J Pharm Sci Res 2021; 12(11): 5642-5651.
2. Chatterjee B, Dash B, Shrestha B and Bhuyan NR: Current scenarios on regulatory landscape of Indian pharmaceutical industries. Int J Pharm Sci Res 2021; 12(11): 5642-5651.
3. Nagalakshmi S, Rao VR and Kumar P: Regulatory prototype for cosmetics in India. Int J Appl Pharm 2021; 13(4): 45-52.
4. Suganthi S, Priya M and Karthik R: Regulatory framework and medical device regulations in India. Int J Pharm Sci Res 2023; 14(10): 4733-4740.
5. Singh A and Patel R: Role of regulatory affairs in pharmaceutical industries. Asian J Pharm Clin Res 2020; 13(5): 12-18.
6. Ministry of Health and Family Welfare: Drugs and Cosmetics Act and Rules 1945. Government of India, New Delhi 1945.
7. Sharma R and Kulkarni P: Counterfeit medicines and regulatory challenges in developing countries. Asian J Pharm 2022; 16(2): 95-103.
8. Gupta N and Sharma V: Regulatory authorities and pharmaceutical regulations in India. Int J Drug Regul Aff 2022; 10(2): 55-63.
9. Pharmacovigilance Programme of India: National Pharmacovigilance Guidelines. Indian Pharmacopoeia Commission, Ghaziabad 2021.
10. World Health Organization: Effective Drug Regulation: A Multicountry Study. WHO Technical Report Series, Geneva 2019.
11. International Council for Harmonisation: International Harmonization in Pharmaceutical Regulations. ICH, Geneva 2021.
12. Patel H and Mehta K: Recent advances in pharmaceutical regulatory systems in India. Pharm Regul Aff J 2022; 9(3): 88-97.
13. Central Drugs Standard Control Organization: CDSCO Organizational Structure and Functions. Ministry of Health and Family Welfare, Government of India, New Delhi 2022.
14. Ministry of Health and Family Welfare: Cosmetic Rules 2020. Government of India, New Delhi 2020.
15. Central Drugs Standard Control Organization: Functions of Drug Controller General of India (DCGI). Government of India, New Delhi 2022.
16. Ministry of Health and Family Welfare: Import and Export Regulations for Pharmaceutical Products. Government of India, New Delhi 2022.
17. Indian Council of Medical Research: National Ethical Guidelines for Biomedical and Health Research Involving Human Participants. ICMR, New Delhi 2017.
18. Ministry of Health and Family Welfare: New Drugs and Clinical Trials Rules 2019. Government of India, New Delhi 2019.
19. World Health Organization: WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. WHO, Geneva 2020.
20. Ministry of Health and Family Welfare: Export Certification Procedures for Pharmaceutical Products. Government of India, New Delhi 2021.
21. Thomas J and Joseph L: Importance of certificate of pharmaceutical product and certificate of analysis in pharmaceutical export. Int J Pharm Investig 2021; 11(2): 104-110.
22. World Health Organization: Good Manufacturing Practices for Pharmaceutical Products. WHO Technical Report Series, Geneva 2020.
23. Central Drugs Standard Control Organization: Guidelines for Quality Control and Documentation Requirements in Pharmaceutical Industries. Government of India, New Delhi 2022.
24. International Council for Harmonisation: Validation of Analytical Procedures and Documentation Requirements. ICH, Geneva 2021.
25. Ministry of Health and Family Welfare: Import and Export Regulations under Drugs and Cosmetics Rules. Government of India, New Delhi 2022.
26. Central Drugs Standard Control Organization: Labeling and Packaging Requirements for Pharmaceuticals and Cosmetics. Government of India, New Delhi 2022.
27. Directorate General of Foreign Trade: Export-Import Policy Guidelines for Pharmaceutical Products. Government of India, New Delhi 2022.
28. Directorate General of Foreign Trade: Export-import policy guidelines for pharmaceutical products. Government of India 2022.
29. Ministry of Health and Family Welfare: Cosmetic Licensing Procedures under Cosmetic Rules 2020. Government of India, New Delhi 2020.
30. Central Drugs Standard Control Organization: Guidelines for Cosmetic Manufacturing and Quality Control Requirements. Government of India, New Delhi 2021.
31. CDSCO: Guidelines for cosmetic manufacturing and quality control requirements. Government of India 2021.
32. Ministry of Health and Family Welfare: Amendments under Drugs and Cosmetics Act and Rules. Government of India, New Delhi 2021.
33. Central Drugs Standard Control Organization: Classification and Regulation of Pharmaceutical and Cosmetic Products in India. Government of India, New Delhi 2022.
34. World Health Organization: Global Benchmarking Tool for Evaluation of National Regulatory Systems. WHO, Geneva 2021.
35. Ministry of Health and Family Welfare: Regulatory Forms under Cosmetic Rules 2020. Government of India, New Delhi 2020.
36. Central Drugs Standard Control Organization: Guidelines for Cosmetic Manufacturing License Application and Renewal Procedures. Government of India, New Delhi 2021.
37. CDSCO: Guidelines for cosmetic manufacturing license application and renewal procedures. Government of India; 2021.
38. Ministry of Electronics and Information Technology: Information Technology Act and Digital Commerce Regulations in India. Government of India, New Delhi 2021.
39. Central Drugs Standard Control Organization: Draft Rules and Guidelines for E Pharmacy Regulation in India. Government of India, New Delhi 2021.
40. Ministry of Health and Family Welfare: Schedule M Requirements for Pharmaceutical Industries. Government of India, New Delhi 2021.
41. International Council for Harmonisation: Data Integrity and Documentation Guidelines. International Council for Harmonisation, Geneva 2021.
42. International Council for Harmonisation: Data integrity and documentation guidelines. International Council for Harmonisation 2021.
43. World Health Organization: Age-Friendly Pharmaceutical Regulations and Medication Safety Guidelines. WHO, Geneva 2021.
44. International Council for Harmonisation: Clinical Investigation Guidelines for Special Populations. ICH, Geneva 2021.
45. World Health Organization: WHO Global Benchmarking Tool (GBT) for Evaluation of National Regulatory System of Medical Products. WHO, Geneva 2024.
46. International Council for Harmonisation: ICH Q9(R1): Quality Risk Management. ICH, Geneva 2023.
47. Ministry of Health and Family Welfare: Amendment to Schedule M under Drugs and Cosmetics Rules 1945 (Good Manufacturing Practices Requirements). Gazette Notification, Government of India, New Delhi 2023.
48. Press Information Bureau: Government Strengthens Drug Regulatory Framework through CDSCO Initiatives. Ministry of Health and Family Welfare, Government of India, New Delhi 2026.
49. International Council for Harmonisation: ICH Guidelines. ICH, Geneva 2025.
    

    ---

    How to cite this article:

    Kanaka VS, Srathika K, Deepu S, Ranitha R, Thomas NA, Apsara R, Nehanaz M, Sandwana T, Fathima MS and Sunaina M: Emerging regulatory framework for pharmaceuticals and cosmetics in India: current perspectives and future challenges. Int J Pharm Sci & Res 2026; 17(11): 3408-28. doi: 10.13040/IJPSR.0975-8232.17(11).3408-28.

    ---

    All © 2026 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.